FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318578194> ?p ?o ?g. }

• W4318578194 endingPage "i682" @default.
• W4318578194 startingPage "i681" @default.
• W4318578194 abstract "Abstract Background Ustekinumab (UST) is an approved treatment for adults with inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]), psoriasis (PsO), and psoriatic arthritis (PsA). Here, we present pooled safety analyses in these approved indications of patients (pts) with active tuberculosis (TB) and opportunistic infections (OIs) through 5 years (yrs) of UST treatment. Methods Pooled data included 13 Phase 2/3 UST studies through 5 yrs of CD and PsO, 2 yrs of UC, and 1 yr of PsA. OIs were identified by clinician review. Herpes zoster (HZ) was evaluated separately. Event rates per 100 pt yrs (PYs) are presented. Concomitant immunomodulators/corticosteroids were permitted in IBD and PsA pts. All pts who received ≥1 UST dose were included. In IBD, placebo (PBO) pts included data up to the first UST dose for pts initially treated with PBO, or &gt;16 weeks after the last UST dose for UST pts who switched to PBO. Results Across all approved indications, 19 OIs including TB were reported, with rates in PBO of 0.40 and UST of 0.10 through 5 yrs in 13807 PYs of follow-up (Table 1); rates of HZ were 1.21 and 0.63, respectively. Of 19 OIs, 18 were in IBD pts and 1 in a PsO pt. Overall, 14/16 pts (12/13 UST) with OIs excluding TB were also receiving confounding concomitant medications. A total of 3 active TB cases (2 pts with CD and 1 pt with UC) were reported in PBO (n=2; 1 in a Hungarian CD pt 10 months after receiving last UST dose) and UST (n=1) pts (Table 1). One active TB case was reported in an asymptomatic South African CD pt treated with UST who had a positive QuantiFERON®-TB Gold test on routine screening and bronchial brushings positive for M. tuberculosis. Both CD pts completed TB treatment with disease resolution. The most common OIs were esophageal candidiasis (UST n=3; PBO n=2) and cytomegalovirus colitis (UST n=3; PBO n=1). Conclusion Rates of OIs, including active TB, in UST-treated pts were low across approved indications through up to 5 yrs with 13807 PYs of follow-up and not higher in UST pts vs PBO pts, suggesting no increased risk of OI with long-term UST treatment." @default.
• W4318578194 created "2023-01-31" @default.
• W4318578194 creator A5000855284 @default.
• W4318578194 creator A5023503974 @default.
• W4318578194 creator A5029768626 @default.
• W4318578194 creator A5034029760 @default.
• W4318578194 creator A5035175414 @default.
• W4318578194 creator A5038275921 @default.
• W4318578194 creator A5048047565 @default.
• W4318578194 creator A5071111368 @default.
• W4318578194 date "2023-01-30" @default.
• W4318578194 modified "2023-09-29" @default.
• W4318578194 title "P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications" @default.
• W4318578194 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0683" @default.
• W4318578194 hasPublicationYear "2023" @default.
• W4318578194 type Work @default.
• W4318578194 citedByCount "0" @default.
• W4318578194 crossrefType "journal-article" @default.
• W4318578194 hasAuthorship W4318578194A5000855284 @default.
• W4318578194 hasAuthorship W4318578194A5023503974 @default.
• W4318578194 hasAuthorship W4318578194A5029768626 @default.
• W4318578194 hasAuthorship W4318578194A5034029760 @default.
• W4318578194 hasAuthorship W4318578194A5035175414 @default.
• W4318578194 hasAuthorship W4318578194A5038275921 @default.
• W4318578194 hasAuthorship W4318578194A5048047565 @default.
• W4318578194 hasAuthorship W4318578194A5071111368 @default.
• W4318578194 hasBestOaLocation W43185781941 @default.
• W4318578194 hasConcept C126322002 @default.
• W4318578194 hasConcept C141071460 @default.
• W4318578194 hasConcept C142724271 @default.
• W4318578194 hasConcept C2776260265 @default.
• W4318578194 hasConcept C2778260677 @default.
• W4318578194 hasConcept C2778975655 @default.
• W4318578194 hasConcept C2779134260 @default.
• W4318578194 hasConcept C2779384505 @default.
• W4318578194 hasConcept C2780132546 @default.
• W4318578194 hasConcept C2780479503 @default.
• W4318578194 hasConcept C2781069245 @default.
• W4318578194 hasConcept C2909065710 @default.
• W4318578194 hasConcept C71924100 @default.
• W4318578194 hasConceptScore W4318578194C126322002 @default.
• W4318578194 hasConceptScore W4318578194C141071460 @default.
• W4318578194 hasConceptScore W4318578194C142724271 @default.
• W4318578194 hasConceptScore W4318578194C2776260265 @default.
• W4318578194 hasConceptScore W4318578194C2778260677 @default.
• W4318578194 hasConceptScore W4318578194C2778975655 @default.
• W4318578194 hasConceptScore W4318578194C2779134260 @default.
• W4318578194 hasConceptScore W4318578194C2779384505 @default.
• W4318578194 hasConceptScore W4318578194C2780132546 @default.
• W4318578194 hasConceptScore W4318578194C2780479503 @default.
• W4318578194 hasConceptScore W4318578194C2781069245 @default.
• W4318578194 hasConceptScore W4318578194C2909065710 @default.
• W4318578194 hasConceptScore W4318578194C71924100 @default.
• W4318578194 hasIssue "Supplement_1" @default.
• W4318578194 hasLocation W43185781941 @default.
• W4318578194 hasOpenAccess W4318578194 @default.
• W4318578194 hasPrimaryLocation W43185781941 @default.
• W4318578194 hasRelatedWork W2012144537 @default.
• W4318578194 hasRelatedWork W2127804484 @default.
• W4318578194 hasRelatedWork W2235471063 @default.
• W4318578194 hasRelatedWork W2755211682 @default.
• W4318578194 hasRelatedWork W2800010837 @default.
• W4318578194 hasRelatedWork W2960380094 @default.
• W4318578194 hasRelatedWork W2990597987 @default.
• W4318578194 hasRelatedWork W3157494418 @default.
• W4318578194 hasRelatedWork W4225758421 @default.
• W4318578194 hasRelatedWork W4226394802 @default.
• W4318578194 hasVolume "17" @default.
• W4318578194 isParatext "false" @default.
• W4318578194 isRetracted "false" @default.
• W4318578194 workType "article" @default.